TOVX - Theriva Biologics, Inc.
0.1808
-0.004 -1.991%
Share volume: 1,557,224
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.26%
PREVIOUS CLOSE
CHG
CHG%
$0.18
0.00
-0.02%
Fundamental analysis
38%
Profitability
35%
Dept financing
33%
Liquidity
50%
Performance
40%
Performance
5 Days
-9.01%
1 Month
-4.84%
3 Months
-18.26%
6 Months
-53.37%
1 Year
-86.61%
2 Year
-60.70%
Key data
Stock price
$0.18
DAY RANGE
$0.18 - $0.18
52 WEEK RANGE
$0.16 - $1.50
52 WEEK CHANGE
-$85.99
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-29-2025
Company detail
CEO: Steven A. Shallcross
Region: US
Website: therivabio.com
Employees: 20
IPO year: 2012
Issue type: Common Stock
Market: NYSE American
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Region: US
Website: therivabio.com
Employees: 20
IPO year: 2012
Issue type: Common Stock
Market: NYSE American
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Synthetic Biologics, Inc. develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade intravenous beta-lactam antibiotics in gastrointestinal (GI) tract. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma.
Recent news